As of 2025-03-17, the Relative Valuation of Akero Therapeutics Inc (AKRO) is (112.77) USD. This relative valuation is based on P/E multiples. With the latest stock price at 44.15 USD, the upside of Akero Therapeutics Inc based on Relative Valuation is -355.4%.
The range of the Relative Valuation is (93.32) - (120.67) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.3x - 49.9x | 41.2x |
| Forward P/E multiples | 26.9x - 40.5x | 34.5x |
| Fair Price | (93.32) - (120.67) | (112.77) |
| Upside | -311.4% - -373.3% | -355.4% |
| Date | P/E |
| 2025-03-04 | -14.95 |
| 2025-03-03 | -15.28 |
| 2025-02-28 | -16.49 |
| 2025-02-27 | -16.03 |
| 2025-02-26 | -15.97 |
| 2025-02-25 | -15.93 |
| 2025-02-24 | -16.65 |
| 2025-02-21 | -17.40 |
| 2025-02-20 | -16.98 |
| 2025-02-19 | -17.01 |
| 2025-02-18 | -16.59 |
| 2025-02-14 | -16.96 |
| 2025-02-13 | -16.52 |
| 2025-02-12 | -16.59 |
| 2025-02-11 | -16.76 |
| 2025-02-10 | -17.17 |
| 2025-02-07 | -18.19 |
| 2025-02-06 | -18.44 |
| 2025-02-05 | -19.32 |
| 2025-02-04 | -18.93 |
| 2025-02-03 | -18.07 |
| 2025-01-31 | -18.15 |
| 2025-01-30 | -18.58 |
| 2025-01-29 | -18.12 |
| 2025-01-28 | -17.28 |
| 2025-01-27 | -17.36 |
| 2025-01-24 | -8.79 |
| 2025-01-23 | -8.78 |
| 2025-01-22 | -8.40 |
| 2025-01-21 | -8.59 |
| 2025-01-17 | -8.44 |
| 2025-01-16 | -8.06 |
| 2025-01-15 | -7.49 |
| 2025-01-14 | -7.34 |
| 2025-01-13 | -7.60 |
| 2025-01-10 | -8.34 |
| 2025-01-08 | -8.78 |
| 2025-01-07 | -8.93 |
| 2025-01-06 | -9.28 |
| 2025-01-03 | -9.48 |
| 2025-01-02 | -9.42 |
| 2024-12-31 | -9.34 |
| 2024-12-30 | -9.38 |
| 2024-12-27 | -9.48 |
| 2024-12-26 | -9.70 |
| 2024-12-24 | -9.59 |
| 2024-12-23 | -9.52 |
| 2024-12-20 | -9.85 |
| 2024-12-19 | -9.53 |
| 2024-12-18 | -9.64 |